Tag: 300-400

Response to Dal-Re and Holm’s ethical concern regarding the UK PANORAMIC COVID-19 trial by the PANORAMIC Investigators was written by Butler, Christopher C.;the PANORAMIC Trial Investigators. And the article was included in British Journal of Clinical Pharmacology in 2022.Application In Synthesis of ((2R,3S,4R,5R)-3,4-Dihydroxy-5-((Z)-4-(hydroxyimino)-2-oxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)methyl isobutyrate The following contents are mentioned in the article:

In this article the author discusses about response to Dal-Re and Holm’s ethical concern regarding UK PANORAMIC COVID-19 trial by PANORAMIC investigators. All participants are able to receive standard best available care, regardless of whether they are receive an antiviral in PANORAMIC or not. If randomized to an anti-viral arm in PANORAMIC, participants who are eligible for CMDU treatment can also be given a neutralizing monoclonal antibody (nMAB) or an antiviral drug outside of PANORAMIC. This is all at the discretion of the clinician in charge at the CMDU. Similarly, if randomized to Usual Care in PANORAMIC, participants can still receive an nMAB or an antiviral agent from a CMDU. The PANORAMIC Trial Website states that some may be eligible to receive antiviral treatment outside of the PANORAMIC Trial and that their clin. care remains under the direction of the NHS. The CDMUs were established to provide access to acute COVID treatments for the highest risk patients, a much smaller eligible population than all people over 50 or over 18 with a COVID risk factor eligible for PANORAMIC. The care pathways are complementary. Further, highest risk patients have been contacted with advice (and a PCR test kit) how to access a CDMU in the event they become infected and CDMUs are also contacting eligible people at highest risk if they test pos. Molnupiravir has conditional marketing approval in the UK, recognizing that clin. data for full authorization are not yet available. PANORAMIC is a key contribution to generate these data. For example, participants in the pivotal phase 3 trial (MOVe-OUT) were unvaccinated, exposed to different variants of SARs-CoV-2 from those in current circulation, and largely recruited in healthcare systems different from the UK. It is important to evaluate whether the treatment effect on which the conditional approval is based applies in a clin. relevant population in the UK. PANORAMIC thus represents a pragmatic means to assess molnupiravir and other potential treatments without denying participants access to treatments available through other approved routes. This study involved multiple reactions and reactants, such as ((2R,3S,4R,5R)-3,4-Dihydroxy-5-((Z)-4-(hydroxyimino)-2-oxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)methyl isobutyrate (cas: 2492423-29-5Application In Synthesis of ((2R,3S,4R,5R)-3,4-Dihydroxy-5-((Z)-4-(hydroxyimino)-2-oxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)methyl isobutyrate).

((2R,3S,4R,5R)-3,4-Dihydroxy-5-((Z)-4-(hydroxyimino)-2-oxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)methyl isobutyrate (cas: 2492423-29-5) belongs to tetrahydrofuran derivatives. Tetrahydrofuran (THF), or oxolane, is mainly used as a precursor to polymers. Being polar and having a wide liquid range, THF is a versatile solvent. Tetrahydrofuran reaction with hydrogen sulfide: In the presence of a solid acid catalyst, tetrahydrofuran reacts with hydrogen sulfide to give tetrahydrothiophene.Application In Synthesis of ((2R,3S,4R,5R)-3,4-Dihydroxy-5-((Z)-4-(hydroxyimino)-2-oxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)methyl isobutyrate

Referemce:
Tetrahydrofuran – Wikipedia,
Tetrahydrofuran | (CH2)3CH2O – PubChem

Astrogliosis in epilepsy leads to overexpression of adenosine kinase, resulting in seizure aggravation. was written by Fedele, Denise E;Gouder, Nicolette;Güttinger, Martin;Gabernet, Laetitia;Scheurer, Louis;Rülicke, Thomas;Crestani, Florence;Boison, Detlev. And the article was included in Brain : a journal of neurology in 2005.Application of 24386-93-4 The following contents are mentioned in the article:

Adenosine kinase (ADK) is considered to be the key regulator of the brain’s endogenous anticonvulsant, adenosine. In adult brain, ADK is primarily expressed in a subpopulation of astrocytes and striking upregulation of ADK in these cells has been associated with astrogliosis after kainic acid-induced status epilepticus (KASE) in the kainic acid mouse model of temporal lobe epilepsy. To investigate the causal relationship between KASE-induced astrogliosis, upregulation of ADK and seizure activity, we have developed a novel mouse model [the Adktm1(-/-)-Tg(UbiAdk) mouse] lacking the endogenous astrocytic enzyme due to a targeted disruption of the endogenous gene, but containing an Adk transgene under the control of a human ubiquitin promoter. Mutant Adktm1(-/-)-Tg(UbiAdk) mice were characterized by increased brain ADK activity and constitutive overexpression of transgenic ADK throughout the brain, with particularly high levels in hippocampal pyramidal neurons. This ADK overexpression was associated with increased baseline levels of locomotion. Most importantly, two-thirds of the mutant mice analysed exhibited spontaneous seizure activity in the hippocampus and cortex. This was the direct consequence of transgene expression, since this seizure activity could be prevented by systemic application of the ADK inhibitor 5-iodotubercidin. Intrahippocampal injection of kainate in the mutant mice resulted in astrogliosis to the same extent as that observed in wild-type mice despite the absence of endogenous astrocytic ADK. Therefore, KASE-induced upregulation of endogenous ADK in wild-type mice is a consequence of astrogliosis. However, seizures in kainic acid-injected mutants displayed increased intra-ictal spike frequency compared with wild-type mice, indicating that, once epilepsy is established, increased levels of ADK aggravate seizure severity. We therefore conclude that therapeutic strategies that augment the adenosine system after astrogliosis-induced upregulation of ADK constitute a neurochemical rationale for the prevention of seizures in epilepsy. This study involved multiple reactions and reactants, such as (2R,3R,4S,5R)-2-(4-Amino-5-iodo-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol (cas: 24386-93-4Application of 24386-93-4).

(2R,3R,4S,5R)-2-(4-Amino-5-iodo-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol (cas: 24386-93-4) belongs to tetrahydrofuran derivatives. THF (Tetrahydrofuran) is a stable compound with relatively low boiling point and excellent solvency. THF (Tetrahydrofuran) is also used as a starting material for the synthesis of poly(tetramethylene ether) glycol (PTMG), etc.Application of 24386-93-4

Referemce:
Tetrahydrofuran – Wikipedia,
Tetrahydrofuran | (CH2)3CH2O – PubChem

Interactions of 5- iodotubercidin with binding site of serine/threonine – protein kinase Haspin; an ONIOM approach study was written by Hadad, Babak Khjalili;Sadeh, Hadis Soltani;Arman, Foroozan;Esmaeilzadeh, Fatemeh. And the article was included in Recent Advances in Electrical Engineering Series in 2012.Synthetic Route of C11H13IN4O4 The following contents are mentioned in the article:

Each daughter cell has to receive the correct complement of chromosomes in mitosis. Some of mitotic kinases are critical to manage individualization of chromosomes. Haspin is newly discovered kinase with regulatory effect. Haspin protein has serine/ threonine kinase activity. Thr 3 of Histone H3 is the only substrate of Haspin to do phosphorylation. Highly potent and selective ligands are developed using organo non-metallic inhibitors. Non- metal centers prepare a big chem. chamber. Uncontrolled growth, survival and metastasis are some characteristics of cancer. These are caused because of perturbation of regulatory signaling pathways specially, kinases. Chems. specifically inhibits such regulators, are targets for chemotherapy. Haspin (PDB ID: 3IQ7) is analyzed in present research. H-bond and Hydrophobic pocket interactions are studied with both docking and ONIOM methods. 5- Iodotubercidin-the mimetic structure of ATP- is one of effective inhibitors. To increase the efficacy and its attraction to binding site of the Haspin, it is suggested to modify the structure of drug to increase H-bond attraction. The main engaged amino acids in binding site that are responsible to produce H- bonds, are Glu⁶⁰⁶, Gly⁶⁰⁸, Asp⁶¹¹ and Gly⁶⁵³. By modifying the drug it is possible to increase some sites, to engage more amino acids, close to present pocket. Gln⁶¹⁴, Arg⁶¹⁶ are closest functional amino acids based on primary structure. The same process will be done for hydrophobic pocket where Ile⁴⁹⁰, Gly⁴⁹¹, Val⁴⁹⁸, Ala⁵⁰⁹, Phe⁶⁰⁹, Leu⁶⁵⁶, and He⁶⁸⁶ are the main amino acids. Phe⁴⁹⁵, Phe⁴⁹⁹, He⁶⁸⁵, Val⁵⁰⁸ and Phe⁶⁰⁵ are suggested to be the next targets. Oxygen and fluorine are found more effective than iodine to make the system more stable. It is suggested to use the oxygen or fluorine as two electroneg. elements instead of the iodine. This study involved multiple reactions and reactants, such as (2R,3R,4S,5R)-2-(4-Amino-5-iodo-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol (cas: 24386-93-4Synthetic Route of C11H13IN4O4).

(2R,3R,4S,5R)-2-(4-Amino-5-iodo-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol (cas: 24386-93-4) belongs to tetrahydrofuran derivatives. Tetrahydrofuran (THF), or oxolane, is mainly used as a precursor to polymers. Being polar and having a wide liquid range, THF is a versatile solvent. Oxidations have also proved to be valuable and efficient approaches to chiral tetrahydrofuran derivatives.Synthetic Route of C11H13IN4O4

Referemce:
Tetrahydrofuran – Wikipedia,
Tetrahydrofuran | (CH2)3CH2O – PubChem

Network Pharmacology and Molecular Docking Approaches to Investigating the Mechanism of Action of Zanthoxylum bungeanum in the Treatment of Oxidative Stress-induced Diseases was written by Zhao, Rong;Zhang, Meng-Meng;Wang, Dan;Peng, Wei;Zhang, Qing;Liu, Jia;Ai, Li;Wu, Chun-Jie. And the article was included in Combinatorial Chemistry & High Throughput Screening in 2021.Synthetic Route of C11H13IN4O4 The following contents are mentioned in the article:

Zanthoxylum bungeanum Maxim., a traditional Chinese herbal medicine, has been reported to possess therapeutic effects on diseases induced by oxidative stress (DOS), such as atherosclerosis and diabetes complication. However, the active components and their related mechanisms are still not systematically reported. The current study was aimed to explore the main active ingredients and their mol. mechanisms of Z. bungeanum for treating DOS using network pharmacol. combined with mol. docking simulation. The active components of Z. bungeanum pericarps, in addition to the interacting targets, were identified from the Traditional Chinese Medicine Systems Pharmacol. (TCMSP) database. These components were filtered using the parameters of oral bioavailability and drug-likeness, and the targets related to DOS were obtained from the Genecards and OMIM database. Furthermore, the overlapping genes were obtained, and a protein-protein interaction was visualized using the STRING database. Next, the Cytoscape software was employed to build a disease/drug/component/target network, Gene Ontol. (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment anal. were performed using R software. Finally, the potential active compounds and their related targets were validated using mol. docking technol. A total of 61 active compounds, 280 intersection genes, and 105 signaling pathways were obtained. Functional enrichment anal. suggested that DOS occurs possibly through the regulation of many biol. pathways, such as AGE-RAGE and HIF-1 signaling pathways. Thirty of the identical target genes showed obvious compact relationships with others in the STRING anal. Three active compounds, quercetin, diosmetin, and beta-sitosterol, interacting with the four key targets, exhibited strong affinities. The findings of this study not only indicate the main mechanisms involving in oxidative stress-induced diseases but also provide the basis for further research on the active components of Z. bungeanum for treating DOS. This study involved multiple reactions and reactants, such as (2R,3R,4S,5R)-2-(4-Amino-5-iodo-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol (cas: 24386-93-4Synthetic Route of C11H13IN4O4).

(2R,3R,4S,5R)-2-(4-Amino-5-iodo-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol (cas: 24386-93-4) belongs to tetrahydrofuran derivatives. THF (Tetrahydrofuran) is a stable compound with relatively low boiling point and excellent solvency. Commercial tetrahydrofuran contains substantial water that must be removed for sensitive operations, e.g. those involving organometallic compounds. Although tetrahydrofuran is traditionally dried by distillation from an aggressive desiccant, molecular sieves are superior.Synthetic Route of C11H13IN4O4

Referemce:
Tetrahydrofuran – Wikipedia,
Tetrahydrofuran | (CH2)3CH2O – PubChem

Predominance of adenosine excitatory over inhibitory effects on transmission at the neuromuscular junction of infant rats was written by Pousinha, Paula A.;Correia, Alexandra M.;Sebastiao, Ana M.;Ribeiro, Joaquim A.. And the article was included in Journal of Pharmacology and Experimental Therapeutics in 2010.Safety of (2R,3R,4S,5R)-2-(4-Amino-5-iodo-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol The following contents are mentioned in the article:

Adenosine-induced modulation of neuromuscular transmission in young (3-4-wk-old) rats was evaluated. Inhibition of adenosine kinase with iodotubercidin (ITU; 10 μM), which is known to induce adenosine release, enhanced the amplitude of evoked end-plate potentials (EPPs) recorded from innervated diaphragm muscle fibers. This facilitatory effect was transformed into an inhibitory one upon blockade of adenosine A_2A receptors with 4-(2-[7-amino-2-(2-furly)[1,2,4]triazolo[2,3-a][1,3,5]triazin5ylamino] ethyl) phenol (ZM 241385) (50 nM); further blockade of adenosine A₁ receptors with the selective antagonist 1,3-dipropyl-8-cyclopentylxanthine (DPCPX; 10 nM) abolished that inhibition. Adenosine or 2-chloroadenosine (CADO), at submicromolar concentrations, increased the amplitude and the quantal content of EPPs, whereas at low micromolar concentrations they decreased EPP amplitude. Blockade of A₁ receptors with DPCPX (10 nM) prevented both excitatory and inhibitory effects, whereas blockade of A_2A receptors with ZM241385 (50 nM) prevented only the excitatory effects. DPCPX and ZM241385 also prevented the excitatory effect of the selective A_2A receptor agonist 2-[p-(2-carboxyethyl) phenethylamino]-5′-N-ethylcarboxamido adenosine hydrochloride (CGS 21680; 10 nM). CADO (30 nM) also increased neuromuscular transmission in adult (12-16-wk-old) rats. It is suggested that at the motor nerve endings, low extracellular concentrations of adenosine activate both A_2A and A₁ receptors, but activation of A_2A receptors predominates over A₁ receptors; the activity of A_2A receptors might, however, require coactivation of A₁ receptors. This facilitatory action of low concentrations of extracellular adenosine upon acetylcholine release may be particularly relevant at developing neuromuscular junctions, where subtle changes in synaptic levels of acetylcholine might influence synaptic stabilization. This study involved multiple reactions and reactants, such as (2R,3R,4S,5R)-2-(4-Amino-5-iodo-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol (cas: 24386-93-4Safety of (2R,3R,4S,5R)-2-(4-Amino-5-iodo-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol).

(2R,3R,4S,5R)-2-(4-Amino-5-iodo-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol (cas: 24386-93-4) belongs to tetrahydrofuran derivatives. Tetrahydrofurans and furans are important oxygen-containing heterocycles that often exhibit interesting properties for biological applications or applications in the cosmetic industry. It is more basic than diethyl ether and forms stronger complexes with Li+, Mg2+, and boranes. It is a popular solvent for hydroboration reactions and for organometallic compounds such as organolithium and Grignard reagents.Safety of (2R,3R,4S,5R)-2-(4-Amino-5-iodo-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol

Referemce:
Tetrahydrofuran – Wikipedia,
Tetrahydrofuran | (CH2)3CH2O – PubChem

Development of off-line and on-line capillary electrophoresis methods for the screening and characterization of adenosine kinase inhibitors and substrates was written by Iqbal, Jamshed;Burbiel, Joachim C.;Mueller, Christa E.. And the article was included in Electrophoresis in 2006.Recommanded Product: 24386-93-4 The following contents are mentioned in the article:

Fast and convenient CE assays were developed for the screening of adenosine kinase (AK) inhibitors and substrates. In the first method, the enzymic reaction was performed in a test tube and the samples were subsequently injected into the capillary by pressure and detected by their UV absorbance at 260 nm. An MEKC method using borate buffer (pH 9.5) containing 100 mM SDS (Method: A) was suitable for separating alternative substrates (nucleosides). For the CE determination of AMP formed as a product of the AK reaction, a phosphate buffer (pH 7.5 or 8.5) was used and a constant current (95 μA) was applied (Method: B). The methods employing a fused-silica capillary and normal polarity mode provided good resolution of substrates and products of the enzymic reaction and a short anal. time of less than 10 min. To further optimize and miniaturize the AK assays, the enzymic reaction was performed directly in the capillary, prior to separation and quantitation of the product employing electrophoretically mediated microanal. (EMMA, Method: C). After hydrodynamic injection of a plug of reaction buffer (20 mM Tris-HCl, 0.2 mM MgCl₂, pH 7.4), followed by a plug containing the enzyme, and subsequent injection of a plug of reaction buffer containing 1 mM ATP, 100 μM adenosine, and 20 μM UMP as an internal standard (I.S.), as well as various concentrations of an inhibitor, the reaction was initiated by the application of 5 kV separation voltage (neg. polarity) for 0.20 min to let the plugs interpenetrate. The voltage was turned off for 5 min (zero-potential amplification) and again turned on at a constant current of -60 μA to elute the products within 7 min. The method employing a polyacrylamide-coated capillary of 20 cm effective length and reverse polarity mode provided good resolution of substrates and products. Dose-response curves and calculated K_i values for standard antagonists obtained by CE were in excellent agreement with data obtained by the standard radioactive assay. This study involved multiple reactions and reactants, such as (2R,3R,4S,5R)-2-(4-Amino-5-iodo-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol (cas: 24386-93-4Recommanded Product: 24386-93-4).

(2R,3R,4S,5R)-2-(4-Amino-5-iodo-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol (cas: 24386-93-4) belongs to tetrahydrofuran derivatives. Tetrahydrofuran (THF) is a Lewis base that bonds to a variety of Lewis acids such as I2, phenols, triethylaluminum and bis(hexafluoroacetylacetonato)copper(II). Tetrahydrofuran (THF) is primarily used as a precursor to polymers including for surface coating, adhesives, and printing inks.Recommanded Product: 24386-93-4

Referemce:
Tetrahydrofuran – Wikipedia,
Tetrahydrofuran | (CH2)3CH2O – PubChem

Application In Synthesis of (2R,3S,4S,5S)-5-(Acetoxymethyl)tetrahydrofuran-2,3,4-triyl triacetateIn 2005, Herbal, Karim;Kitteringham, John;Voyle, Martyn;Whitehead, Andrew J. published 《Synthesis of the enantiomer of nelarabine》. 《Tetrahedron Letters》published the findings. The article contains the following contents:

A synthesis of the enantiomer of nelarabine is described. Subtle changes in the protecting group strategy allow for an efficient inversion of the C-2′ stereocentre. The experimental procedure involved many compounds, such as (2R,3S,4S,5S)-5-(Acetoxymethyl)tetrahydrofuran-2,3,4-triyl triacetate (cas: 144490-03-9) .

(2R,3S,4S,5S)-5-(Acetoxymethyl)tetrahydrofuran-2,3,4-triyl triacetate(cas:144490-03-9 Application In Synthesis of (2R,3S,4S,5S)-5-(Acetoxymethyl)tetrahydrofuran-2,3,4-triyl triacetate) is an isomer of 1,2,3,5-Tetra-O-acetyl β-D-Ribofuranose (T283100) which is used in the synthesis of 3-(β-D-ribofuranosyl)-2,3-dihydro-6H-1,3-oxazine-2,6-dione, a new pyrimidine nucleoside analog related to uridine.

Reference:
Tetrahydrofuran – Wikipedia,
Tetrahydrofuran | (CH2)3CH2O – PubChem

Electric Literature of C13H18O9《β-L-Thymidine 5′-triphosphate analogs as DNA polymerase substrates》 was published in 1992. The authors were Van Draanen, Nanine A.;Tucker, S. Craig;Boyd, F. Leslie;Trotter, B. Wesley;Reardon, John E., and the article was included in《Journal of Biological Chemistry》. The author mentioned the following in the article:

β-L-3′-Deoxythymidine 5′-triphosphate (L-ddTTP) and β-L-3′-deoxy-2′,3′-didehydrothymidine 5′-triphosphate (L-d4TTP) were substrates for human immunodeficiency virus (HIV) reverse transcriptase, Escherichia coli DNA polymerase I (Klenow), and Sequenase (modified T7 DNA polymerase). The β-D– and β-L-enantiomers of 5-methyluridine 5′-triphosphate (rTTP) were inhibitors but not substrates of reverse transcriptase. The steady-state K_m values for L-ddTTP and L-d4TTP, with all three enzymes, were 12-70-fold larger than the K_m values for the corresponding D-enantiomers. The K_m value of reverse transcriptase for L-ddTTP was 50-fold larger than that for D-ddTTP because the K_d for L-ddTTP was 5-fold larger than that for D-ddTTP, and the first-order rate constant for incorporation of L-ddTMP into the template-primer was 10% that of the D-enantiomer. The D– and L-enantiomers had k_cat values with reverse transcriptase and Sequenase that were similar to k_cat for the natural substrate, thymidine 5′-triphosphate (dTTP). Thus, the rate determining step appeared to be dissociation of the enzyme-chain-terminated template-primer complex. In contrast, k_cat values for the L-enantiomers with Klenow were only 0.1% that of dTTP, and the k_cat values for the D-enantiomers were 15% the k_cat for dTTP. The reduced k_cat values were due to a change in rate-determining step from dissociation of the Klenow-chain-terminated template-primer complex to an earlier step in the reaction mechanism, presumably catalysis. Thus, these DNA polymerases did not stereospecifically recognize D-nucleoside 5′-triphosphate analogs as substrates. The virucidal activity of some nucleoside analogs against HIV is discussed on the basis of the above results. The experimental procedure involved many compounds, such as (2R,3S,4S,5S)-5-(Acetoxymethyl)tetrahydrofuran-2,3,4-triyl triacetate (cas: 144490-03-9) .

(2R,3S,4S,5S)-5-(Acetoxymethyl)tetrahydrofuran-2,3,4-triyl triacetate(cas:144490-03-9 Electric Literature of C13H18O9) is an isomer of 1,2,3,5-Tetra-O-acetyl β-D-Ribofuranose (T283100) which is used in the synthesis of 3-(β-D-ribofuranosyl)-2,3-dihydro-6H-1,3-oxazine-2,6-dione, a new pyrimidine nucleoside analog related to uridine.

Reference:
Tetrahydrofuran – Wikipedia,
Tetrahydrofuran | (CH2)3CH2O – PubChem

Chan, Joseph H.;Chamberlain, Stanley D.;Biron, Karen K.;Davis, Michelle G.;Harvey, Robert J.;Selleseth, Dean W.;Dornsife, Ronna E.;Dark, Ernest H.;Frick, Lloyd W.;Townsend, Leroy B.;Drach, John C.;Koszalka, George W. published 《Synthesis and evaluation of a series of 2′-deoxy analogues of the antiviral agent 5,6-dichloro-2-isopropylamino-1-(β-L-ribofuranosyl)-1H-benzimidazole (1263W94)》. The research results were published in《Nucleosides, Nucleotides & Nucleic Acids》 in 2000.Reference of (2R,3S,4S,5S)-5-(Acetoxymethyl)tetrahydrofuran-2,3,4-triyl triacetate The article conveys some information:

A series of 2′-deoxy analogs of the antiviral agent 5,6-dichloro-2-isopropylamino-1-(β-L-ribofuranosyl)-1H-benzimidazole (1263W94) were synthesized and evaluated for activity against human cytomegalovirus (HCMV) and for cytotoxicity. The 2-substituents in the benzimidazole moiety correspond to those that were used in the 1263W94 series. In general, as was found in the 1263W94 series, cyclic and branched alkylamino groups were needed for potent activity against HCMV. Three analogs were as potent as 1263W94. Further evaluation of two analogs suggested that these 2′-deoxy analogs may act via a novel mechanism of action similar to that of 1263W94. These 2′-deoxy analogs generally lacked cytotoxicity in vitro. Pharmacokinetic parameters in mice and protein binding properties of one of the analogs (I) were quite similar to 1263W94. However, the oral bioavailability of I was only half of that observed for 1263W94. The experimental procedure involved many compounds, such as (2R,3S,4S,5S)-5-(Acetoxymethyl)tetrahydrofuran-2,3,4-triyl triacetate (cas: 144490-03-9) .

(2R,3S,4S,5S)-5-(Acetoxymethyl)tetrahydrofuran-2,3,4-triyl triacetate(cas:144490-03-9 Reference of (2R,3S,4S,5S)-5-(Acetoxymethyl)tetrahydrofuran-2,3,4-triyl triacetate) is an isomer of 1,2,3,5-Tetra-O-acetyl β-D-Ribofuranose (T283100) which is used in the synthesis of 3-(β-D-ribofuranosyl)-2,3-dihydro-6H-1,3-oxazine-2,6-dione, a new pyrimidine nucleoside analog related to uridine.

Reference:
Tetrahydrofuran – Wikipedia,
Tetrahydrofuran | (CH2)3CH2O – PubChem

Shi, Z.-D.;Yang, B.-H.;Wu, Y.-L. published 《A stereospecific synthesis of L-ribose and L-ribosides from D-galactose》. The research results were published in《Tetrahedron Letters》 in 2001.Computed Properties of C13H18O9 The article conveys some information:

An inexpensive D-galactose was converted into L-ribose and its derivatives via mild reaction conditions. The L-ribosyl donor was submitted to a glycosidation according to Vorbruggen’s conditions to give L-riboside nucleosides, e.g. L-adenosine, in high yields. And (2R,3S,4S,5S)-5-(Acetoxymethyl)tetrahydrofuran-2,3,4-triyl triacetate (cas: 144490-03-9) was used in the research process.

(2R,3S,4S,5S)-5-(Acetoxymethyl)tetrahydrofuran-2,3,4-triyl triacetate(cas:144490-03-9 Computed Properties of C13H18O9) is an isomer of 1,2,3,5-Tetra-O-acetyl β-D-Ribofuranose (T283100) which is used in the synthesis of 3-(β-D-ribofuranosyl)-2,3-dihydro-6H-1,3-oxazine-2,6-dione, a new pyrimidine nucleoside analog related to uridine.

Reference:
Tetrahydrofuran – Wikipedia,
Tetrahydrofuran | (CH2)3CH2O – PubChem